Serum paraoxonase activity in patients with low glomerular filtration rates

REFERENCES

• Mcclellan WM, Knight DF, Karp H, Brown WW. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: Important differences between practice and published guidelines. Am J Kidney Dis. 1997;29:368–375.
   PubMed Web of Science ®Google Scholar
• Kausz AT, Khan SS, Abıchandanı R, Management of patients with chronic renal insufficiency in the northeastern United States. J Am Soc Nephrol. 2001;12:1501–1507.
   PubMed Web of Science ®Google Scholar
• Coresh J, Astor BC, Green T, Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12.
   PubMed Web of Science ®Google Scholar
• Panzetta O, Cominacini L, Garbin U, Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: Effects of fish oil and vitamin E administration. Clin Nephrol. 1995;44:303–309.
   PubMed Web of Science ®Google Scholar
• Cristol JP, Dantoine T, Morena M, Protective effects of HDL against oxidative stress is impaired in hemodialysis patients. Nephrol Dial Transplant. 1997;12:A156.
   Google Scholar
• Witztum IL. The oxidation hypothesis of atherosclerosis. Lancet. 1994;344:793–795.
   PubMed Web of Science ®Google Scholar
• Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286:152–154.
   PubMed Web of Science ®Google Scholar
• Shih DM, Xia YR, Wang XP, Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem. 2000;275:17527–17535.
   PubMed Web of Science ®Google Scholar
• Watson AD, Berliner JA, Hama SY, Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882–2891.
   PubMed Web of Science ®Google Scholar
• Watson AD, Navab M, Hama SY, Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995;95:774–782.
   PubMed Web of Science ®Google Scholar
• Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med. 2004;37:1304–1316.
   PubMed Web of Science ®Google Scholar
• Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: Is the gene or the protein more important? Free Radic Biol Med. 2004;37:1317–1323.
   PubMed Web of Science ®Google Scholar
• Jarvik GP, Rozek LS, Brophy VH, Furlong CE Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol. 2000;20:2441–2447.
   PubMed Web of Science ®Google Scholar
• Mackness B, Durrington P, Mc Elduff P, Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003;107:2775–2779.
   PubMed Web of Science ®Google Scholar
• Sarandol A, Sarandol E, Eker SS, Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1103–1108.
   PubMed Web of Science ®Google Scholar
• Gomez-Farices MA, McClellan W, Soucie JM, Mitch WE. A prospective comparison of methods for determining if cardiovascular disease is a predictor of mortality in dialysis patients. Am J Kidney Dis. 1994;23:382–388.
   PubMed Web of Science ®Google Scholar
• Owen WF, Madore F, Brenner BM. An observational study of cardiovascular characteristics of long-term end-stage renal disease survivors. Am J Kidney Dis. 1996;28:931–936.
   PubMed Web of Science ®Google Scholar
• Girotti AW. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res. 1998;39:1529–1542.
   PubMed Web of Science ®Google Scholar
• Isik A, Koca SS, Ustundag B, Celik H, Yildirim A. Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin Rheumatol. 2007;26:342–348.
   PubMed Web of Science ®Google Scholar
• Gorog P, Kotak DC, Kovacs IB. Simple and specific test for measuring lipid peroxides in plasma. J Clin Pathol. 1991;44:765–767.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. Clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:1–266.
   PubMed Web of Science ®Google Scholar
• Oberg BP, McMenamin E, Lucas FL, Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65:1009–1016.
   PubMed Web of Science ®Google Scholar
• Vanholder R, Argıles A, Baurmeıster U, Uremic toxicity: Present state of the art. Int J Artif Organs. 2001;24:695–725.
   PubMed Web of Science ®Google Scholar
• Dubourg L, Mıchoudet C, Cochat P, Baverel G. Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol. 2001;12:1615–1623.
   PubMed Web of Science ®Google Scholar
• Mıhoudet C, Baverel G. Metabolism of acetaldehyde in human and baboon renal cortex. FEBS Lett. 1987;216:113–117.
   PubMed Web of Science ®Google Scholar
• Stuveling EM, Hillege HL, Bakker SJ, C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int. 2003;63:654–661.
   PubMed Web of Science ®Google Scholar
• Pecoits-Filho R, Heimburger O, Barany P, Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41:1212–1218.
   PubMed Web of Science ®Google Scholar
• Panichi V, Migliori M, De Pietro S, C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron. 2002;91:594–600.
   PubMed Web of Science ®Google Scholar
• Descamps-Latscha B, Herbelın A, Nguyen AT, Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis: Relationships with activation markers of T cells, B cells, and monocytes. J Immunol. 1995;154:882–892.
   PubMed Web of Science ®Google Scholar
• Dantoine TF, Debord J, Charmes JP, Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol. 1998;9:2082–2088.
   PubMed Web of Science ®Google Scholar
• Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G. Serum paraoxonase is decreased in uremic patients. Clin Chim Acta. 1996;247:71–80.
   PubMed Web of Science ®Google Scholar
• Bolton CH, Downs LG, Victory JGG, Endothelial dysfunction in chronic renal failure: Roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2001;16:1189–1197.
   PubMed Web of Science ®Google Scholar
• Mezzano D, Pais EO, Aranda E, Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int. 2001;60:1844–1850.
   PubMed Web of Science ®Google Scholar
• Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol. 1998;161:2524–2532.
   PubMed Web of Science ®Google Scholar